ArticleBMC cancer2026
Diagnostic value of 18 F-FDG PET-CT combined with ultrasound-guided percutaneous core needle biopsy for patients with primary gastrointestinal lymphomas: a multicenter study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the efficacy and safety of 18 F-FDG PET-CT combined with ultrasound-guided percutaneous core needle biopsy in diagnosing primary gastrointestinal lymphomas (PGILs).
methodsPatients with suspected PGILs who were admitted to Fujian Provincial Hospital and Fujian Medical University Union Hospital between January 2014 and April 2022 were selected; gastrointestinal hypermetabolic lesions were identified with 18 F-FDG PET-CT, and ultrasound-guided percutaneous core needle biopsies were performed accordingly. Patients confirmed with PGILs by endoscopic biopsy or after-resection biopsy during the same period were included in the control groups. Intergroup comparisons were made in the aspects of complications after biopsy, histopathological sampling satisfaction, days between biopsy and the initiation of chemotherapy, and expenses.
resultsOf 98 patients included in the study, 20 were in the ultrasound-guided percutaneous core needle biopsy group, 44 in the endoscopic biopsy group and 34 in the after-resection biopsy group. All patients were histopathologically diagnosed with non-Hodgkin’s lymphomas. The sampling success rates were 90% for the ultrasound-guided percutaneous core needle biopsy group, 100% for the after-resection biopsy group, and 75% for the endoscopic biopsy group. No patient in the ultrasound-guided percutaneous core needle biopsy group developed complications (e.g., local hemorrhage, perforation and infection). One patient (2.2%) in the endoscopic biopsy group experienced hemorrhage. The complication incidence rates of the after-resection biopsy group (fever, 32.3%; infection, 20.5%) were much higher. For the ultrasound-guided percutaneous core needle biopsy group, the procedure durations were 14.45 ± 1.93 min, the days between biopsy and the initiation of chemotherapy were 9.80 ± 4.26 days, and the biopsy-associated costs RMB5,505 ± 1,743; all conspicuously lower than those for the endoscopic biopsy group and the after-resection biopsy group (P < 0.001).
conclusion18 F-FDG PET-CT combined with ultrasound-guided percutaneous core needle biopsy is safer, more effective and faster in diagnosing PGILs than endoscopic biopsy or surgical biopsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.